NDAINJECTIONINJECTABLE
Approved
Jul 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TOBRAMYCIN SULFATE (tobramycin sulfate) by Fresenius Kabi is mechanism of action tobramycin acts by inhibiting synthesis of protein in bacterial cells. Approved for prosthetic joint infection. First approved in 2004.
Drug data last refreshed 21h ago
Mechanism of Action
Mechanism of Action Tobramycin acts by inhibiting synthesis of protein in bacterial cells. In vitro tests demonstrate that tobramycin is bactericidal.
Worked on TOBRAMYCIN SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.